Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies	Advanced Malignancies	Active, not recruiting	Phase 1	2026-02-12		NCT03233139

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Regeneron Pharmaceuticals	238

20 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Gunma Prefectural Cancer Center	Ōta	Japan	5
Hiroshima City Hiroshima Citiz	Hiroshima	Japan	2
Kanagawa Cancer Center - Thora	Yokohama	Japan	1
Kanagawa Cardiovascular and Respiratory Center	Yokohama	Japan	5
Kanazawa University Hospital	Kanazawa	Japan	34
Kansai Medical University Hirakata Hospital	Hirakata	Japan	1
Kitasato University Hospital	Sagamihara	Japan	12
Kobe City Medical Center General Hospital	Kobe	Japan	25
Kurashiki Central Hospital	Kurashiki	Japan	6
Kurume University Hospital	Kurume	Japan	25
Nagasaki University Hospital	Nagasaki	Japan	36
National Cancer Center Hospital - Tsukiji Campus	Chuo Ku	Japan	2
National Hospital Organization Kinki-chuo Chest Medical Center	Sakai-shi	Japan	4
National Hospital Organization Nagoya Medical Center	Nagoya	Japan	8
Osaka International Cancer Institute	Osaka	Japan	43
Osaka Medical and Pharmaceutical University Hospital	Takatsuki	Japan	7
Osaka Metropolitan University Hospital	Osaka	Japan	14
Saitama Cancer Center	Shinden	Japan	3
Sasebo City General Hospital	Sasebo	Japan	1
Tokushima University Hospital	Tokushima	Japan	15

Clinical trials